Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report

RATIONALE: Tyrosine kinase inhibitors (TKIs) are known to have greater efficacy in epidermal growth factor receptor (EGFR) mutation nonsmall cell lung cancer (NSCLC). However, about 10% of EGFR wild-type (wt) patients respond to TKIs. PATIENT CONCERNS: Several strategies to increase the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tongpeng, Wu, Hao, Jin, Shidai, Min, Huang, Zhang, Zhihong, Shu, Yongqian, Wen, Wei, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571687/
https://www.ncbi.nlm.nih.gov/pubmed/28816950
http://dx.doi.org/10.1097/MD.0000000000007732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571687/
https://www.ncbi.nlm.nih.gov/pubmed/28816950
http://dx.doi.org/10.1097/MD.0000000000007732

Ejemplares similares